## New York College of Health Professions Institutional Review Board for Research with Human Subjects (IRB) Unanticipated Problem/Adverse Event Report/ Unanticipated Adverse Device Effect for NYCHP Subjects

Please review the IRB's policy on Unanticipated Problems and Adverse Events found at (<a href="https://nycollege.edu/">https://nycollege.edu/</a>).

| Date of this Report:   |  |   |                              |  |  |  |  |
|--|--|---|------------------------------|--|--|--|--|
| -  |  |   | NYCHP Sch                    | ool/Center:  |  |  |  |
| Project Title:   |  |   |                              |  |  |  |  |
|  |  |   |                              |  |  |  |  |
| Principal Investig   | ator Info  | rmation   |                              |  |  |  |  |
| Name   |  |   |                              | Relationship to NSU:   |  |  |  |
| Home Mailing Address (for students)  |  |   |                              | Faculty  |  |  |  |
| Tromo maming radioses (ier stademe)  |  |   |                              | Staff □  |  |  |  |
| City/State/Zip:  |  |   |                              | Student  |  |  |  |
|  |  | ome Phone (for students):   |                              | Email:   |  |  |  |
|  | L  |   |                              | I  |  |  |  |
| Study Sponsor:   |  |   |                              |  |  |  |  |
| Has the sponsor b  | een notif  | ied?  |                              |  |  |  |  |
| Yes   No   |  |   |                              |  |  |  |  |
| Date of Notification   | n:   |   |                              |  |  |  |  |
| Submit 1 Adverse nature of the adver   | Event Re<br>se event                                 | dverse Event/Unanti<br>port for each subject.<br>If a separate notification | You may use ation is require | e additional sheets  | to describe the                        |  |  |
| Participant #  | Participant # Date of Description of Unanticipated P |   |                              | em/Adverse Event   | Was the Adverse                        |  |  |
|  | Adverse<br>Event                                     | <b>;</b>  |                              |  | Event Unexpected? Yes  No              |  |  |
|  |  |   |                              |  |  |  |  |
| Was the Adverse Event Serious?<br>Yes □ No □   |  |   |                              |  | es the adverse event suggests that the |  |  |
|  |  |   |                              | earch places subjects or others at a greater of harm? Yes □ No □ |  |  |  |
|  |  |   |                              |  |  |  |  |
| Should the protocol and/or consent forms be revised Yes   No   No  |  |   |                              | Will additional information be given to enrolled subjects?       |  |  |  |
| Does the event have implications for the conduct of the study?   |  |   |                              | Yes □ No □   |  |  |  |
| Yes  No  | <b>.</b>   |   |                              |  |  |  |  |
| If Yes, please submit a copy of the corrected amendment forms with <b>bold</b> changes and a clean copy incorporating the changes. |  |   |                              |  |  |  |  |
| <b>y</b> ·   |  | .,, ,   | <u> </u>                     |  |  |  |  |
| Principal Investigator's Signature   |  |   |                              | Date.  |  |  |  |

## New York College of Health Professions Institutional Review Board IND Safety Report

| Date:                          | IRB Protocol #:                       | IRB Protocol #: |  |  |
|--------------------------------|---------------------------------------|-----------------|--|--|
| Principal Investigator:        | NYCHP School/Center:                  |                 |  |  |
| Project Title:                 |                                       |                 |  |  |
|                                |                                       |                 |  |  |
| Study Sponsor:                 |                                       |                 |  |  |
| IND Safety Report dated:       |                                       |                 |  |  |
| Serious Adverse Event / Ser    | tinel Event Information:              |                 |  |  |
| Description of Serious or Sent | nel Event Date of event               |                 |  |  |
| I have personally reviewed the | IND safety report of a serious advers | se event        |  |  |
| Principal Investigator         | Date                                  |                 |  |  |

## **DEFINITONS**:

1. Unanticipated Problems (non FDA research) are considered to include any incident, experience, or outcome that meets all of the following criteria:

Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related outcomes, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied;

Related or possibly related to participation in the research (possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research; and

Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

2. For FDA governed research, please note that the criteria of an unanticipated problem is slightly different.

Unexpected

Serious

Would have implications for the conduct of the study (e.g., requiring a significant, and usually safety-related, change in the protocol such as revising inclusion/exclusion criteria or including a new monitoring requirement, informed consent, or investigator's brochure).

3. Serious Adverse Events are defined as follows:

Death

Congenital Anomaly/Birth Defect

Hospitalization Required or Prolongation of a Hospitalization

Life Threatening Event

Significant or Persistent Disability/Incapacity

**IND Safety reports** are generated when a serious adverse event which may be related to the study drug and not expected occurs in any protocol using the study drug. IND safety reports must be reported to the IRB in keeping with the Unanticipated Problems and Adverse Event Reporting policy.